Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets

Li, Lisha; Lu, Jiaye; Liu, Jun; Wu, Junchao; Zhang, Xinyue; Meng, Yu; Wu, Xiying; Tai, Zongguang; Zhu, Quangang; Chen, Zhongjian

doi:10.3389/fimmu.2023.1340677

Cited by 11 publications

(4 citation statements)

References 283 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Psoriasis is often triggered by infections and other various factors, resulting in metabolic abnormality and an imbalance in immune modulation [ 31 , 32 ]. Inflammatory cell infiltration is among the important pathological features [ 33 , 34 ]. Psoriasis is indeed a cytokine-driven inflammatory skin disease in which interferon (IFN)-γ, TNFα, IL-17, and IL-22 cytokines have a pathogenic action [ 35 – 38 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Oxymatrine in the Treatment of Patients with Erythrodermic Psoriasis

Shi,

Chen,

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction The management of erythrodermic psoriasis (EP), a rare but severe type of psoriasis, is challenging, especially in patients with concomitant chronic hepatitis B (CHB). We previously demonstrated that oxymatrine treatment alleviated severe plaque psoriasis, but its therapeutic potential in treating EP remains unexplored. This study was to assess the efficacy and safety of oxymatrine for the treatment of EP, with attention to concomitant CHB. Methods In this investigator-initiated clinical trial, four consecutive patients with EP, including two (A and B) with concomitant CHB, were treated with intravenous administration of oxymatrine as monotherapy for 8 weeks, and scheduled to be followed up for a minimum of 24 weeks. The primary outcome was at least 75% improvement in the psoriasis area and severity index (PASI 75) at week 32. Secondary outcomes included the body surface area (BSA) score, dermatology life quality index (DLQI)], and safety. Results Patients A, B, and C achieved PASI 75 at treatment completion and week 32, demonstrating improvements of 77.4%, 97.2%, and 100% in PASI, respectively. Their BSA and DLQI were also improved significantly at week 32 and throughout follow-up of 37, 57, and 105 weeks, respectively. The viral loads in patients A and B with CHB decreased modestly. Patient D discontinued after follow-up for 19 weeks, and the primary outcome could not be analyzed. No adverse events were reported during treatment and follow-up. Conclusion Oxymatrine appears to be efficacious and safe for the treatment of patients with EP, including those with concomitant CHB. Trial Registration This study was registered at the Chinese Clinical Trial Registry ( www.chictr.org.cn ; Registration number ChiCTR-TRC-14004301). Supplementary Information The online version contains supplementary material available at 10.1007/s13555-024-01181-5.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Oxymatrine in the Treatment of Patients with Erythrodermic Psoriasis

Shi,

Chen,

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…Both of these findings indicate a greater immune cell presence in the IMQ-treated skin. The increase in the severity and spread of psoriasis correlates with the increase in the number of inflammatory markers [ 24 ]. The higher number of immune cells in the IMQ-treated murine model parallels this progression.…”

Section: Discussionmentioning

confidence: 99%

The Efficacy of Imiquimod-Induced Psoriasis Model on Murine Cells

Joseph,

Genkin,

Genkin

et al. 2024

Cureus

View full text Add to dashboard Cite

Keratinocytes are an essential component of the epidermis that undergoes constant proliferation and differentiation. However, the dysregulation of keratinocyte differentiation has been implicated in various skin disorders such as psoriasis. Imiquimod, otherwise known as IMQ, is a topical immunomodulator often used to induce psoriasis-like lesions in murine models for research purposes. This study focuses on the efficacy of using IMQ to induce a psoriasis-like model on murine skin cells by analyzing single-cell RNA sequencing and trajectory analysis. The results indicate a few differences between IMQ-induced and control murine cells, primarily the increased keratinocyte and immune cell populations, which reflects the cell identity found on psoriatic skin. However, trajectory analysis reveals that IMQ-induced cells have quite a linear differentiation pattern compared to the branched pattern found in control cells. As a result, further research must be conducted to explore differing factors between psoriatic cells and IMQ-induced cells to determine its usefulness in mimicking psoriasis-like conditions for research.

show abstract

“…These findings strongly suggest that macrophages are involved in both disease initiation and maintenance. Finally, imiquimod, acting as a TLR7 and TLR8 agonist, can directly activate macrophages and promote their M1 polarization [50] in a 4-1BBL-dependent manner [51], which seems to be pivotal in psoriasis pathogenesis [52].…”

Section: Macrophage Functions In Mouse Psoriatic Inflammationmentioning

confidence: 99%

Macrophage Functions in Psoriasis: Lessons from Mouse Models

Nazimek,

Bryniarski

2024

IJMS

View full text Add to dashboard Cite

Psoriasis is a systemic autoimmune/autoinflammatory disease that can be well studied in established mouse models. Skin-resident macrophages are classified into epidermal Langerhans cells and dermal macrophages and are involved in innate immunity, orchestration of adaptive immunity, and maintenance of tissue homeostasis due to their ability to constantly shift their phenotype and adapt to the current microenvironment. Consequently, both macrophage populations play dual roles in psoriasis. In some circumstances, pro-inflammatory activated macrophages and Langerhans cells trigger psoriatic inflammation, while in other cases their anti-inflammatory stimulation results in amelioration of the disease. These features make macrophages interesting candidates for modern therapeutic strategies. Owing to the significant progress in knowledge, our review article summarizes current achievements and indicates future research directions to better understand the function of macrophages in psoriasis.

show abstract

Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets

Cited by 11 publications

References 283 publications

Efficacy and Safety of Oxymatrine in the Treatment of Patients with Erythrodermic Psoriasis

Efficacy and Safety of Oxymatrine in the Treatment of Patients with Erythrodermic Psoriasis

The Efficacy of Imiquimod-Induced Psoriasis Model on Murine Cells

Macrophage Functions in Psoriasis: Lessons from Mouse Models

Contact Info

Product

Resources

About